anti-VEGFs.<\/strong>
\nThese treatments must be renewed regularly depending on the reappearance of new vessels.
\nThis intravitreal injection is performed on an outpatient basis under local anesthesia and presents few complications.<\/p>\nResearchers have just discovered an enzyme involved in this disease, which opens the way to new research that could prove promising.
\nIndeed, an American team has just discovered that retinal atrophy is linked to the absence of DICER-1, an enzyme that plays a protective role.
\nThis DICER-1 enzyme prevents the accumulation of Alu RNA, which is toxic to the cells of the eye. Thus, when the quantity of DICER-1 enzyme decreases, the Alu RNA accumulates in too great a quantity and leads to the destruction of the retina.
\nScientists have therefore developed techniques to either stimulate the DICER-1 enzyme or block the Alu RNA by eliminating it.
\nThe first trials seem conclusive, but we must now move on to clinical trials on patients suffering from age-related macular degeneration.<\/p>\n
Visual aid rehabilitation<\/h2>\n
In the case of advanced AMD, when treatments are insufficient in terms of visual acuity, rehabilitation may be offered.<\/p>\n
Low vision orthoptic rehabilitation aims to teach patients to use their peripheral vision to compensate for the loss of central vision. This does not improve the remaining vision but it allows an improvement in everyday gestures.
\nIn addition to rehabilitation, visual aids can be useful such as: magnifying glasses, video magnifiers, more powerful lighting.<\/p>\n
Dietary supplementation<\/h2>\n
Studies show the benefits that certain foods can bring to AMD, particularly zinc and Omega 3.<\/p>","protected":false},"excerpt":{"rendered":"
DMLA : comment traiter une d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l’\u00e2ge La DMLA (d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l’\u00e2ge) de forme \u00ab\u00a0humide\u00a0\u00bb a grandement b\u00e9n\u00e9fici\u00e9 de l’arriv\u00e9e des nouveaux traitements anti-VEGF sous forme d’injection intra-vitr\u00e9enne. D’autres traitements sont encore propos\u00e9s tels que la phototh\u00e9rapie dynamique et Laser Argon. Pour les formes atrophiques trop \u00e9volu\u00e9es et la forme […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":76,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-82","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"http:\/\/www.vision-laser.fr\/en\/wp-json\/wp\/v2\/pages\/82","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.vision-laser.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/www.vision-laser.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/www.vision-laser.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.vision-laser.fr\/en\/wp-json\/wp\/v2\/comments?post=82"}],"version-history":[{"count":16,"href":"http:\/\/www.vision-laser.fr\/en\/wp-json\/wp\/v2\/pages\/82\/revisions"}],"predecessor-version":[{"id":1643,"href":"http:\/\/www.vision-laser.fr\/en\/wp-json\/wp\/v2\/pages\/82\/revisions\/1643"}],"up":[{"embeddable":true,"href":"http:\/\/www.vision-laser.fr\/en\/wp-json\/wp\/v2\/pages\/76"}],"wp:attachment":[{"href":"http:\/\/www.vision-laser.fr\/en\/wp-json\/wp\/v2\/media?parent=82"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}